Initial testing of the Aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)

John M. Maris, Christopher L. Morton, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, Jianrong Wu, Malcolm A. Smith, Peter J. Houghton

Research output: Contribution to journalArticle

156 Citations (Scopus)

Abstract

Background. MLN8237 is a small molecule inhibitor of Aurora Kinase A (AURKA) that is currently in early phase clinical testing. AURKA plays a pivotal role in centrosome maturation and spindle formation during mitosis. Procedures. MLN8237 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro panel at concentrations ranging from 1.0 nM to 10 μM and was tested against the PPTP in vivo panels at a dose of 20 mg/kg administered orally twice daily x 5 days. Treatment duration was 6 weeks for solid tumor xenografts and 3 weeks for ALL xenografts. Results. MLN8237 had a median IC50 of 61 nM against the PPTP in vitro panel. The ALL cell lines were more sensitive and the rhabdomyosarcoma cell lines less sensitive than the remaining PPTP cell lines. In vivo, MLN8237 induced significant differences in event-free survival (EFS) distributions compared to controls in 32/40 (80%) solid tumor models and all (6/6) ALL models. Maintained complete responses (CRs) were observed in 3 of 7 neuroblastoma xenografts, and all 6 evaluable ALL xenografts achieved CR (n=4) or maintained CR (n=2) status. Maintained CRs were observed among single xenografts in other panels, including the Wilms tumor, rhabdoid tumor, rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, and medulloblastoma. Conclusions. The in vivo activity observed against the neuroblastoma panel far exceeds that observed for standard agents evaluated against the panel by the PPTP. High levels of in vivo activity were also observed against the ALL xenograft panel. These data support expedited clinical development of MLN8237 in childhood cancer.

Original languageEnglish (US)
Pages (from-to)26-34
Number of pages9
JournalPediatric Blood and Cancer
Volume55
Issue number1
DOIs
StatePublished - Jul 15 2010

Fingerprint

Aurora Kinases
Heterografts
Pediatrics
Aurora Kinase A
Rhabdomyosarcoma
Neuroblastoma
Cell Line
Rhabdoid Tumor
Neoplasms
Centrosome
Medulloblastoma
Ewing's Sarcoma
Wilms Tumor
Osteosarcoma
Mitosis
Inhibitory Concentration 50
Disease-Free Survival
MLN 8237

Keywords

  • Developmental therapeutics
  • MLN8237
  • Preclinical testing

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Maris, J. M., Morton, C. L., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., ... Houghton, P. J. (2010). Initial testing of the Aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatric Blood and Cancer, 55(1), 26-34. https://doi.org/10.1002/pbc.22430

Initial testing of the Aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). / Maris, John M.; Morton, Christopher L.; Gorlick, Richard; Kolb, E. Anders; Lock, Richard; Carol, Hernan; Keir, Stephen T.; Reynolds, C. Patrick; Kang, Min H.; Wu, Jianrong; Smith, Malcolm A.; Houghton, Peter J.

In: Pediatric Blood and Cancer, Vol. 55, No. 1, 15.07.2010, p. 26-34.

Research output: Contribution to journalArticle

Maris, JM, Morton, CL, Gorlick, R, Kolb, EA, Lock, R, Carol, H, Keir, ST, Reynolds, CP, Kang, MH, Wu, J, Smith, MA & Houghton, PJ 2010, 'Initial testing of the Aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)', Pediatric Blood and Cancer, vol. 55, no. 1, pp. 26-34. https://doi.org/10.1002/pbc.22430
Maris, John M. ; Morton, Christopher L. ; Gorlick, Richard ; Kolb, E. Anders ; Lock, Richard ; Carol, Hernan ; Keir, Stephen T. ; Reynolds, C. Patrick ; Kang, Min H. ; Wu, Jianrong ; Smith, Malcolm A. ; Houghton, Peter J. / Initial testing of the Aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). In: Pediatric Blood and Cancer. 2010 ; Vol. 55, No. 1. pp. 26-34.
@article{37623bfd2e4a4d958ff31fda86448a86,
title = "Initial testing of the Aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)",
abstract = "Background. MLN8237 is a small molecule inhibitor of Aurora Kinase A (AURKA) that is currently in early phase clinical testing. AURKA plays a pivotal role in centrosome maturation and spindle formation during mitosis. Procedures. MLN8237 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro panel at concentrations ranging from 1.0 nM to 10 μM and was tested against the PPTP in vivo panels at a dose of 20 mg/kg administered orally twice daily x 5 days. Treatment duration was 6 weeks for solid tumor xenografts and 3 weeks for ALL xenografts. Results. MLN8237 had a median IC50 of 61 nM against the PPTP in vitro panel. The ALL cell lines were more sensitive and the rhabdomyosarcoma cell lines less sensitive than the remaining PPTP cell lines. In vivo, MLN8237 induced significant differences in event-free survival (EFS) distributions compared to controls in 32/40 (80{\%}) solid tumor models and all (6/6) ALL models. Maintained complete responses (CRs) were observed in 3 of 7 neuroblastoma xenografts, and all 6 evaluable ALL xenografts achieved CR (n=4) or maintained CR (n=2) status. Maintained CRs were observed among single xenografts in other panels, including the Wilms tumor, rhabdoid tumor, rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, and medulloblastoma. Conclusions. The in vivo activity observed against the neuroblastoma panel far exceeds that observed for standard agents evaluated against the panel by the PPTP. High levels of in vivo activity were also observed against the ALL xenograft panel. These data support expedited clinical development of MLN8237 in childhood cancer.",
keywords = "Developmental therapeutics, MLN8237, Preclinical testing",
author = "Maris, {John M.} and Morton, {Christopher L.} and Richard Gorlick and Kolb, {E. Anders} and Richard Lock and Hernan Carol and Keir, {Stephen T.} and Reynolds, {C. Patrick} and Kang, {Min H.} and Jianrong Wu and Smith, {Malcolm A.} and Houghton, {Peter J.}",
year = "2010",
month = "7",
day = "15",
doi = "10.1002/pbc.22430",
language = "English (US)",
volume = "55",
pages = "26--34",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Initial testing of the Aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)

AU - Maris, John M.

AU - Morton, Christopher L.

AU - Gorlick, Richard

AU - Kolb, E. Anders

AU - Lock, Richard

AU - Carol, Hernan

AU - Keir, Stephen T.

AU - Reynolds, C. Patrick

AU - Kang, Min H.

AU - Wu, Jianrong

AU - Smith, Malcolm A.

AU - Houghton, Peter J.

PY - 2010/7/15

Y1 - 2010/7/15

N2 - Background. MLN8237 is a small molecule inhibitor of Aurora Kinase A (AURKA) that is currently in early phase clinical testing. AURKA plays a pivotal role in centrosome maturation and spindle formation during mitosis. Procedures. MLN8237 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro panel at concentrations ranging from 1.0 nM to 10 μM and was tested against the PPTP in vivo panels at a dose of 20 mg/kg administered orally twice daily x 5 days. Treatment duration was 6 weeks for solid tumor xenografts and 3 weeks for ALL xenografts. Results. MLN8237 had a median IC50 of 61 nM against the PPTP in vitro panel. The ALL cell lines were more sensitive and the rhabdomyosarcoma cell lines less sensitive than the remaining PPTP cell lines. In vivo, MLN8237 induced significant differences in event-free survival (EFS) distributions compared to controls in 32/40 (80%) solid tumor models and all (6/6) ALL models. Maintained complete responses (CRs) were observed in 3 of 7 neuroblastoma xenografts, and all 6 evaluable ALL xenografts achieved CR (n=4) or maintained CR (n=2) status. Maintained CRs were observed among single xenografts in other panels, including the Wilms tumor, rhabdoid tumor, rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, and medulloblastoma. Conclusions. The in vivo activity observed against the neuroblastoma panel far exceeds that observed for standard agents evaluated against the panel by the PPTP. High levels of in vivo activity were also observed against the ALL xenograft panel. These data support expedited clinical development of MLN8237 in childhood cancer.

AB - Background. MLN8237 is a small molecule inhibitor of Aurora Kinase A (AURKA) that is currently in early phase clinical testing. AURKA plays a pivotal role in centrosome maturation and spindle formation during mitosis. Procedures. MLN8237 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro panel at concentrations ranging from 1.0 nM to 10 μM and was tested against the PPTP in vivo panels at a dose of 20 mg/kg administered orally twice daily x 5 days. Treatment duration was 6 weeks for solid tumor xenografts and 3 weeks for ALL xenografts. Results. MLN8237 had a median IC50 of 61 nM against the PPTP in vitro panel. The ALL cell lines were more sensitive and the rhabdomyosarcoma cell lines less sensitive than the remaining PPTP cell lines. In vivo, MLN8237 induced significant differences in event-free survival (EFS) distributions compared to controls in 32/40 (80%) solid tumor models and all (6/6) ALL models. Maintained complete responses (CRs) were observed in 3 of 7 neuroblastoma xenografts, and all 6 evaluable ALL xenografts achieved CR (n=4) or maintained CR (n=2) status. Maintained CRs were observed among single xenografts in other panels, including the Wilms tumor, rhabdoid tumor, rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, and medulloblastoma. Conclusions. The in vivo activity observed against the neuroblastoma panel far exceeds that observed for standard agents evaluated against the panel by the PPTP. High levels of in vivo activity were also observed against the ALL xenograft panel. These data support expedited clinical development of MLN8237 in childhood cancer.

KW - Developmental therapeutics

KW - MLN8237

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=77952703733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952703733&partnerID=8YFLogxK

U2 - 10.1002/pbc.22430

DO - 10.1002/pbc.22430

M3 - Article

C2 - 20108338

AN - SCOPUS:77952703733

VL - 55

SP - 26

EP - 34

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -